contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


nexstim-receives-system-order-from-distributor-in-the-middle-east

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

2025’s Store Finale: Indblik i det bedste fra Keiretsu Forum Virtual Investment Showcase                   linkedin.com              2025’s Grand Finale: Inside the Best of Keiretsu Forum Virtual Investment...    In the final weeks of 2025, the US early-stage investment community turned its attention to one place: the Best of Keiretsu Forum Virtual Investment Showcase. Over two days, more than 1,287 investors, family offices, and innovators registered for the...                             Bedst inden for Life Science: Sinaptica Therapeutics, Inmedix, Healionics

Ventetiden er nogle gange lang, men nu har den føltes meget lang for os, der overvåger handelsnyheder om morgenen. Det er dog værd at vente på det gode, det skal man huske på og ikke give plads til usikkerhed. Kursen er jo steget med 7,60 euro, 110%, på et år, og der kan stadig være flere lignende år forude.

Sinapticas finansieringsrunde fortsætter:                   Sinaptica Therapeutics™ - Noninvasive Neuromodulation: A True Breakthrough in... – 11 Dec 25              Sinaptica Therapeutics Receives Funding from The Centre for Aging + Brain...    Cambridge, MA – December 10, 2025 – Sinaptica Therapeutics, Inc., a clinical-stage company leading the development of a new class of personalized neuromodulation therapeutics to treat Alzheimer’s and other primary neurodegenerative diseases, has...

Jeg lever nu stadig i den tro, at de også ville blive meddelt. Hvilken interesse ville det være for Nexstim at holde sådan en positiv overraskelse hemmelig? Jeg fastholder min holdning om, at en betydelig Brainlab-handel først starter næste år og i høj grad følger den tidligere nævnte 18 måneders salgspipeline-gennemløbstid.

Kunne denne kalender også tages som en bekræftelse på, at enheder, der er gået gennem Brainlab, ikke længere bliver pressemeddelt?

Som barn var man nogle gange skuffet over spejdernes kalender, når der ikke kom chokolade ud af den. Denne kalender har indtil videre været endnu mere ubrugelig, men forhåbentlig begynder der senest i næste uge at komme mere interessante låger!

Kedelige billeder og dårligt med chokolade  mon det ender med, at den fjerne slægtning først giver gaver næste år?

Nexstim

Press release, Helsinki, 27 June 2025 at 9 AM (EEST) Nexstim Receives System Order from Distributor in the Middle EastNexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for...

Press release, Helsinki, 27 June 2025 at 9 AM (EEST)&nbsp;Nexstim Receives System Order from Distributor in the Middle EastNexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS System 5 from a distributor for a clinic in the Middle East. The end customer is new to Nexstim.The Nexstim Navigated Brain Stimulation (NBS) System 5 ordered includes a therapy module, allowing the system to be used for the treatment of major depression and chronic neuropathic pain. The end customer intends to use the system mainly in therapy and potentially also for research purposes.Mikko Karvinen, CEO of Nexstim, comments: “With the hard work and expertise of both our international Nexstim team as well as our distributors, we have continued to achieve system sales to different kinds of customers in a large geographical area. Happy to see the efforts pay off as we near the end of the first half of the year.”Further information is available on the website www.nexstim.com, or by contacting: Mikko Karvinen, CEO+358 50 326 4101mikko.karvinen@nexstim.com&nbsp;About Nexstim Plc Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for presurgical mapping of the speech and motor cortices of the brain.Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain.Nexstim shares are listed on Nasdaq First North Growth Market Finland.For more information, please visit <a href="http://www.nexstim.com/">www.nexstim.com </a> <div> <hr> <div>Attachments</div> <div><a href="https://storage.googleapis.com/inderes-widgets-prod-assets/nexstim/attachments/7eefaaa2-f08e-4b27-b6c4-56c915a95b10/nexstim-plc-press-release-me-order-27062025-final.pdf">Nexstim Plc_Press release_ME order_27062025_FINAL.pdf</a></div> </div>